2663-S2 AMS HSC S4963.3
2SHB 2663 - S COMM AMD
By Committee on Human Services & Corrections
NOT ADOPTED 3/3/00
Strike everything after the enacting clause and insert the following:
"NEW SECTION. Sec. 1. The legislature finds that schizophrenia is a devastating and costly disease. Atypical antipsychotic medications have been developed for treatment of schizophrenia and other similar psychiatric and neurological conditions, which have been effective at treating these conditions with less severe side effects than the side effects that accompany typical antipsychotics. In order to protect the public health, safety, and welfare, and reduce the economic and societal costs associated with untreated schizophrenia and other similar psychiatric and neurological conditions, the legislature intends to promote access to atypical antipsychotic medications by those unable to access them and who present a risk of harm to themselves and to the community.
NEW SECTION. Sec. 2. A new section is added to chapter 74.09 RCW to read as follows:
(1) To the extent funds are appropriated, the department of social and health services shall develop a distribution mechanism that promotes access to atypical antipsychotic medications to persons suffering from schizophrenia, or other psychiatric or neurological condition that is treated with atypical antipsychotic medication, who is an offender identified under RCW 72.09.370, or a person identified under RCW 71.05.235 or 10.77.090(1)(d). The department is authorized to establish rules necessary to implement the provisions of this act.
(2) "Atypical antipsychotic medications" means drugs with a pharmacological classification of dibenzodiazepines, benzisoxazoles, and thienobenzodiazepines.
(3) Under this program, the department shall purchase and distribute only those atypical antipsychotic medications whose manufacturers agree to provide a rebate for drugs purchased under the medical care services program, as defined in RCW 74.09.010. The rebate provided for the medical care services program shall be equivalent to, and subject to the same terms and conditions as, the manufacturer's rebate required for drugs purchased under Title XIX of the federal social security act.
(4) Nothing in this section creates or provides any individual with an entitlement to services or benefits. It is the intent of the legislature that atypical antipsychotic medications shall be made available under this section only to the extent of the availability and level of appropriation made by the legislature.
(5) The distribution mechanism shall require successful recipients to comply with data collection needs of the institute.
NEW SECTION. Sec. 3. (1) The Washington state institute for public policy shall conduct an evaluation of this act to determine the following:
(a) Outcomes for persons receiving atypical antipsychotic medications under the provisions of this act, including, but not limited to the person's: (i) Ability to perform basic living skills and maintain a job; (ii) adherence to medication regimens; (iii) number of inpatient placement or acute care services after having received atypical antipsychotic medications; and (iv) criminal conviction record for further offenses, if any, after having received atypical antipsychotic medications;
(b) The extent to which this act increases access to atypical antipsychotic medications to the targeted population; and
(c) The uniformity by health care providers in prescribing atypical antipsychotic medications among the population identified under the provisions of this act.
(2) The institute shall report to the legislature by January 1, 2002."
2SHB 2663 - S COMM AMD
By Committee on Human Services & Corrections
NOT ADOPTED 3/3/00
On page 1, line 2 of the title, after "populations;" strike the remainder of the title and insert "adding a new section to chapter 74.09 RCW; and creating new sections."
--- END ---